BACKGROUND
Driven by the rising health care costs and variation in the quality of medical care observed across providers and regions, [1] [2] [3] private and government payers are searching for approaches to improve value, defined as health outcomes per dollar spent. 4 One approach is to encourage patients to seek care at centers of excellence 5 -hospitals that are expected to provide higher-value care. The Centers of Medicare and Medicaid Services (CMS) recently enacted a policy to only cover bariatric surgery cases performed at a center of excellence. 6 Cigna, Aetna, and other health plans as well as professional organizations are also designating centers of excellence for a broad range of conditions and procedures. [7] [8] [9] The goal of such programs is to drive quality improvement by encouraging patients to obtain their care at these centers, thereby yielding better overall outcomes, lower costs, and thus greater value.
A variety of methods are used to designate centers of excellence. One commonly used criterion is the volume of cases, because a large number of studies have demonstrated better outcomes in higher-volume hospitals. 2, 10 However, volume explains only some of the variation in outcomes. 11 Recent centers of excellence programs require that hospitals meet a broader set of evidence-based criteria, 12 including volume, training of providers, 13 availability of computerized physician order entry, 14, 15 performance on process quality metrics, 16 discharge planning, 17 and nursing-patient ratios. 18, 19 Although evidence exists to support each of the individual criteria used to select centers of excellence, there remains a need to systematically evaluate whether centers of excellence have better outcomes and costs. 20 Recent evaluations of CMS's bariatric surgery centers of excellence program found no clinically significant differences in outcomes or costs. 21, 22 The purpose of this study is to evaluate a centers of excellence program established in 2008 for knee and hip replacement. Knee and hip replacement are an important focus for centers of excellence programs because they are elective inpatient procedures that are performed frequently, and outcomes vary across hospitals. [23] [24] [25] To be designated as a center of excellence in this program, hospitals complete an application form that includes selection criteria that focus on quality such as surgeon and hospital volume, use of multidisciplinary care pathways and teams, electronic medical records and patient data management and tracking, and length of stay (Table 1 ). In this study, we compare the outcomes and costs associated with knee and hip replacement in 43 states between 647 hospitals designated as centers of excellence and 2149 other hospitals.
METHODS

Data Sources
We analyzed all inpatient and outpatient health insurance claims for the years 2007-2009 of approximately 54 million members from 19 health plans in the consortium. We matched hospitals with at least 1 knee or hip replacement in the claims to the 2008 American Hospital Association (AHA) database that contains data on hospital characteristics. On the basis of Medicare hospital identifiers in the AHA data, we extracted 2008 hospital-level data on patient experience (Hospital Consumer Assessment of Healthcare Providers and Systems) 26 and surgical quality measures [Surgical Care Improvement Project (SCIP)] 27 from the Medicare Hospital Compare database.
Patient Sample
We identified all patients in the deidentified claims database with an inpatient hospitalization for a primary total knee or hip replacement during a 27-month period between July 1, 2007 and September 30, 2009 . This 27-month study period allows for a 180-day "clean period" before each initial procedure and a 90-day follow-up period after each procedure. We used International Classification of Diseases, Ninth Revision, Clinical Modification procedure codes 81.54 to identify primary knee replacement and 81.51 for primary hip replacement. We excluded the following patients: aged younger than 18 or older than 65 years; living outside the United States; not continuously enrolled in the health plan for 6 months before and 3 months after the procedure (except those who died); patients for whom the health plan was not the primary insurer; revision knee or hip replacement (respectively); bilateral or multiple procedures; hip hemiarthroplasty (hip analysis); another knee or hip replacement in the 6 months before procedure (respectively); pathologic fracture, bone cancer, metastatic cancer, joint infection, knee fracture (knee analysis); pelvic or femoral fracture (hip analysis); and those who left the hospital against medical advice. The justification for these criteria (including prior studies who have used the same criteria), number of cases excluded, and diagnosis codes used to identify patients are provided in Appendix (Supplemental Digital Content 1, http://links.lww.com/MLR/A344).
Hospital Sample and Analysis of Hospital Characteristics
We identified all hospitals in the AHA database with at least 1 knee or hip replacement patient in our sample. Among these, we identified all hospitals designated as a center of excellence for knee and hip replacement surgery (designation process was started in 2009 and completed in 2010). All other hospitals were classified as "other hospitals." We excluded all hospitals in 7 states (Alaska, Delaware, Mississippi, Oklahoma, Vermont, West Virginia, and Wyoming), in which none of the hospitals applied to the designation program. Our concern was that hospitals in these states that could qualify as a center of excellence would be labeled as "other hospitals." Such misclassification could bias us to the null. Twenty-two hospitals that applied to the program met the criteria in Table 1 to be designated, but did not meet certain business requirements (eg, provider network participation). In our analyses, we classified these hospitals as designated, but they are not listed on the center of excellence website that the consortium maintains.
Outcome Measures
We used 2 main clinical outcome measures: a composite complications rate and an all-cause readmission rate. These measures were developed recently for the CMS by researchers at Yale University. Details and specifications are published elsewhere. 28 These measures were validated by comparing the complication rate as measured by claims versus medical charts for 644 patients. The overall agree-ment was 93%. In addition to the composite complications rate, we also calculated separate rates of 9 individual complications that make up the composite (acute myocardial infarction, pneumonia, sepsis/septicemia, pulmonary embolism, wound infection, surgical-site bleeding, death, periprosthetic joint infection, or mechanical complication).
We identified complications in the initial hospitalization or a readmission to any hospital using specific diagnosis and procedure codes within a specified time period, which varies by complication (detailed in Appendix, Supplemental Digital Content 1, http://links.lww.com/MLR/ A344). Consistent with prior work, 29, 30 we restricted complications to those associated with a hospitalization, because the expert panel who developed the measures felt that they represent more serious complications and therefore are less likely to be biased by differences in coding. A patient rehospitalized could have been at home or at a rehabilitation facility. Mortality was identified based on the discharge status of the initial admission and of other admissions occurring within 30 days of discharge, because information on mortality after discharge was not available from another data source. This differs from the CMS measure that specifies a 30-day mortality rate after the admission date. 31 The readmission rate includes all hospitalizations for any reason within 30 days of the discharge date for the initial stay. However, planned readmissions for another knee or hip replacement (contralateral procedure), and admissions or transfers to an acute rehabilitation hospital or skilled nursing facility were excluded from the readmission rate. Transfer to another acute care hospital was considered a "readmission" (Appendix includes detailed specifications Supplemental Digital Content 1, http://links.lww.com/MLR/A344).
Our other outcome was 90-day total costs for knee and hip replacement. This 90-day cost measure included the costs for every service (eg, rehabilitation services, follow-up hospitalizations, home health) from the initial procedure admission date to 90 days after that date. Pharmacy costs were not included because pharmacy claims data were not available for all patients. The 90-day period, used in prior joint replacement studies, 32 has face validity because the majority of costs in this period are related to the joint replacement and follow-up care. The costs for each service used were the "allowed amount," which is the sum of health plan reimbursement and any patient copayment or deductible. Explicit payments for graduate or indirect medical education are not made by the health plans. To address the concern that costs unrelated to the joint replacement might bias any observed differences, sensitivity analyses on the cost measure were conducted using the publicly available Prometheus Payment algorithm. [33] [34] [35] [36] On the basis of diagnosis and procedure codes in claims data, this algorithm classifies claims as "related to" and "not related to" the joint replacement. Details on the Prometheus algorithm are available in Appendix, Supplemental Digital Content 1, http://links.lww.com/MLR/A344.
Covariates
We adjusted for differences in patient characteristics that might impact the comparison of the 2 sets of hospitals using risk-adjustment models based on the specifications for the CMS complication measures for knee and hip replacement. 28 Patient covariates included in all models were age, sex, and 26 comorbidities (listed in Appendix, Supplemental Digital Content 1, http://links.lww.com/MLR/A344). We identified patients as having a comorbidity based on diagnoses coded on inpatient and outpatient hospital and physician claims during the 6 months before the knee or hip replacement. We chose a 6-month period, instead of the 12-month period specified in the Yale measures, because we were limited by the time period of the claims data available. The comorbidities were classified using Condition Categories from the CMS Hierarchical Condition Category Model (see Appendix, Supplemental Digital Content 1, http://links.lww.com/MLR/A344).
Statistical Analysis
We conducted all statistical analyses using SAS Enterprise Guide Version 4.2 (SAS Institute, Cary, NC, 2010). For all descriptive analyses, we tested for differences between designated hospitals and other hospitals using w 2 tests for categorical data and t tests for continuous data.
To examine the association between complication or readmission rates and designated hospital status, we used multivariate logistic regression models. The unit of the analysis was a hospitalization for knee or hip replacement. The main predictor variable was whether the hospital was designated as a center of excellence. Each model adjusts for the patient covariates described above. For models that did not converge, an abbreviated list of comorbidities was substituted for the list of 26 comorbidities in the model (listed in Appendix, Supplemental Digital Content 1, http://links. lww.com/MLR/A344). Clustering of cases within hospitals was addressed using the Taylor series linearization method. Because of the low complication and readmission rates, use of hospital random effects in those models was not feasible.
To examine the relationship between the costs and designated hospital status, we used multivariate models with a gamma distribution and log link. A gamma model was used because costs were not normally distributed. 37 The outcome variable for the model was the 90-day treatment cost, which is inclusive of costs during the initial hospitalization and the subsequent 90 days after procedure. The main predictor variable was whether the hospital was a designated hospital. Each model also includes the patient covariates described above (ie, age, sex, and 26 comorbidities). To address clustering of cases we used a hierarchical model with a random effect for each hospital. 11, 38 To account for regional variation in factors associated with costs, we included a fixed effect for each state. Coefficients in log link models can be interpreted as the percentage difference in costs associated with a unit change in the independent variable. To assess how well covariates in the model control for differences in patient characteristics between the 2 sets of hospitals, we conducted sensitivity analyses in which we added 6-month baseline costs as an independent variable to the model. Because highcost and low-cost outliers could represent cases with erroneous data, we conducted sensitivity analyses eliminating outliers. Details on these sensitivity analyses are available in Appendix, Supplemental Digital Content 1, http://links. lww.com/MLR/A344. Approval for this study was obtained from the RAND Human Subjects Protection Committee.
RESULTS
Hospital Characteristics
Of the 2796 hospitals with a knee or hip replacement, 647 (23%) were designated as centers of excellence for knee and hip replacement. Compared with other hospitals, these designated hospitals were more likely to be larger, academic, urban, located in the midwest and northeast, and had more surgical cases per year ( Table 2 ). Compared with other hospitals, designated hospitals generally performed better on the SCIP measures ( Table 2) . For example, patients at designated hospitals were more likely to receive deep vein thrombosis prophylaxis (average percentage at designated hospitals and other hospitals, 94.0% and 90.4%, P < 0.01). In contrast, designated hospitals had generally the same or lower results on patient experience measures. For example, the fraction of patients at designated hospitals who would definitely recommend the hospital was lower than at the other hospitals (24.3% and 26.4%, P < 0.01).
Patient Characteristics
Of 80,931 patients with a knee replacement, 42,255 (52.2%) had their surgery at a designated hospital. Of the 39,532 patients with a hip replacement, 22,329 (56.5%) had their surgery at a designated hospital. Comparing knee and hip replacement patients in designated hospitals with those in other hospitals, a slightly lower percentage had hypertension and a slightly higher percentage had vascular disease coded on claims in the 6 months preceding the surgery (Table 3) . Patients at designated hospitals were slightly younger (eg, percentage of patient with hip replacement 18-44, 9.5% designated hospitals vs. 8.7% at other hospitals).
Complication and Readmission Rates
After a total knee replacement, patients at designated hospitals had a lower aggregate complication rate compared with those treated at other hospitals (unadjusted: 2.17% vs. 2.45%). After controlling for patient characteristics, the chance of having a complication was not significantly lower at a designated hospital [odds ratio (OR), 0.90; P = 0.08] ( Table 4 and Fig. 1 ). For specific complications after total knee replacement, there was a lower rate of surgical-site bleeding (OR, 0.41, P < 0.001). There were no significant differences between designated hospitals and other hospitals in the other individual complications.
After a hip replacement, fewer patients had complications at designated hospitals than at other hospitals (unadjusted rates: 2.46% vs. 3.12%). After controlling for patient characteristics, the chance of having a complication was significantly lower at a designated hospital (OR, 0.80; P = 0.002) ( Table 4 and Fig. 1 ). For specific complications after total hip replacement, patients at designated hospitals experienced significantly lower rates of sepsis/septicemia (OR, 0.50; P = 0.003) and wound infection (OR, 0.54; P = 0.001). At designated hospitals, there was a significantly lower 30-day readmission rate than at other hospitals (OR, 0.82; P = 0.003).
Ninety-day Costs
Patients at designated hospitals and other hospitals had similar mean unadjusted 90-day costs for knee replacement ($28,456 and $27,845, respectively) and hip replacement ($27,884 and $28,377, respectively). After controlling for differences in patient characteristics, mean 90-day costs did not differ significantly between designated hospitals and other hospitals for knee replacement (percentage difference, 1.1%; P = 0.37) or for hip replacement (percentage difference, À 0.5%; P = 0.71). In sensitivity analyses, there were no notable differences in the results (Appendix Supplemental Digital Content 1, http://links.lww.com/MLR/A344).
DISCUSSION
Centers of excellence programs are being developed by CMS and individual health plans to improve the value of care received in the health care system. In one of the first evaluations of such a program, we found that there was a 10%-20% reduction in overall complication rates after knee and hip replacement at the hospitals designated as centers of excellence with no difference in costs compared with other hospitals. 39 The difference in complication rates for knee replacement was not statistically significant.
The findings of this study confirm the potential of designating centers of excellence, but suggest that further validation of the selection criteria is warranted. Specifically, our findings for hip replacement support the premise underlying centers of excellence programs: using structural characteristics, it is possible to identify a set of hospitals that on average provide higher-quality care. This is in contrast to a prior evaluation of bariatric surgery centers of excellence, which did not observe differences in outcomes. 21 Our results highlight some of the difficulties of developing valid and clinically significant criteria for centers of excellence. For joint replacement, the observed complication rates were low and therefore the differences in complication rates were low. For example, the difference in hip replacement complication rate between designated hospitals and other hospitals was approximately half a percentage point. Encouraging patients to switch to designated hospitals may be viewed as premature until the selection criteria can identify hospitals with clearly superior outcomes.
Hospitals were designated as centers of excellence based on a long list of criteria (eg, volume, nursing-patient ratios of hospitals). Given the prior literature on the association between outcomes and these criteria, the relatively modest differences we observed are surprising. Recognizing that a panel of experts helped develop the designation criteria, it is possible that the associations between the designation criteria and outcomes in previous studies are weak or spurious. For example, one of the designation criteria is higher performance on the publicly reported CMS SCIP measures, yet recent work showed little relationship between performance on these measures and outcomes. 40 One could attempt to refine the selection criteria to maximize the differences in outcomes between designated and other hospitals. Another option is to designate hospitals based on their complication rate. For example, hospitals with a statistically significant lower complication rate would be designated as a center of excellence. Unfortunately, given the volume of cases and low complication rate we observe, few, if any, hospitals would meet these criteria for hip or knee replacement in our data. We must acknowledge that it may be impossible to identify a set of criteria that identifies hospitals that provide clearly superior care.
One of our hypotheses was that the higher-quality care at designated hospitals would result in fewer complications and, therefore, lower costs. Designated hospitals did exhibit lower complication rates for hip replacement patients, but we did not observe a difference in costs. This finding is consistent with prior studies that have found no association between outcomes and costs. 41 One possible explanation is that complications make only a minor contribution to costs. Because complications were rare events in our data, even if complications increase the costs for an individual patient significantly, the added costs have a small effect on average costs. Therefore, cost differences between hospitals are likely driven by other factors such as geographic variation in utilization 42 or variation in reimbursement. 43 In our analyses, we look at costs from the payer's perspective, which encompasses the provider reimbursement and patient copayments. Therefore, if designated hospitals, which are often academic medical centers, negotiate higher reimbursement, this would mask any cost difference due to a lower complication rate. Future work could use standardized costs for each service to control for these reimbursement differences.
This study is limited by the data available in administrative claims and how we measure costs. Specifically, mortality rates are based on the discharge status of the initial admission and of other admissions occurring within 30 days of discharge. This may result in the overall mortality rate being underestimated. In addition, we did not examine other complications such as deep venous thrombosis. These were not included in the CMS complication measure because this complication is frequently managed as an outpatient and experts felt it may be biased by differences in coding. We measure costs from the payer's perspective and do not address the hospital's costs in providing care or quality improvement initiatives. Information is also not available on variations in negotiated implant costs among providers.
We do not assess the potential impact of this program on many key outcomes including access to care (eg, fraction of patients who have access to a designated hospital), disparities (eg, fraction of low-income patients who choose a designated hospital), or functional outcomes (eg, do patients at designated hospitals have greater improvements in their joint pain). 12 The impact on functional outcomes is important because that is typically why patients have a hip or knee replacement. Given only 3 years of data were available, we were also unable to assess another possible outcomemean time to reoperation. Further, we cannot assess whether there are differences between the 2 sets of hospitals in whether the surgeries performed are appropriate. 44 To the degree that the percentage of patients with more severe or complex illnesses differs between the 2 sets of hospitals and that our inclusions, exclusions, and risk adjustment do not address these differences, our results could be biased. One limitation of claims analyses is that we cannot measure socioeconomic status (eg, income) or important clinical factors (eg, obesity) that might be unmeasured confounders. However, the differences in the patient variables we can capture (eg, age, comorbidities) between the 2 sets of hospitals is relatively small. Claims data are subject to variation in the accuracy and specificity of reporting of complications, which may differ between designated and other hospitals. Some hospitals that would qualify for the designated hospital program may not have submitted an application to become a designated hospital under this program. However, the designation program conducted a follow-up with hospitals that did not respond to the initial call, so there should be few "eligible but not designated" hospitals. Although we analyzed the care of a large and diverse population, our focus is only on patients under 65 years of age with commercial insurance and does not generalize to older patients with Medicare or those with Medicaid.
There are a growing number of health plans and other payers developing centers of excellence, yet there have been few evaluations of the impact of these programs. In our evaluation of 1 program, we found lower complication rates in designated hospitals but similar costs between the 2 sets of hospitals. Such evaluations can help highlight the strengths and weaknesses of the center of excellence approach compared with other approaches to improve health care value, including public reporting of risk-adjusted outcomes 45 and costs 46, 47 and quality improvement initiatives that strive to improve care at all hospitals. 48, 49 
